In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Edge Therapeutics Inc. (NASDAQ:EDGE) reported that Satter Muneer A. has picked up 1,800,000 of common stock as of 2017-04-25.

The acquisition brings the aggregate amount owned by Satter Muneer A. to a total of 1,800,000 representing less than 5.8% stake in the company.

For those not familiar with the company, Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

A glance at Edge Therapeutics Inc. (NASDAQ:EDGE)’s key stats reveals a current market capitalization of 341.17 Million based on 30.81 Million shares outstanding and a price at last close of $10.35 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-06, Loughlin picked up 3,000 at a purchase price of $9.24. This brings their total holding to 6,000 as of the date of the filing.

On the sell side, the most recent transaction saw Leuthner unload 1,500 shares at a sale price of 9.52. This brings their total holding to 245,479.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Edge Therapeutics Inc. (NASDAQ:EDGE) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.